{"id":53075,"date":"2026-01-06T21:07:34","date_gmt":"2026-01-06T13:07:34","guid":{"rendered":"https:\/\/flcube.com\/?p=53075"},"modified":"2026-01-06T21:07:39","modified_gmt":"2026-01-06T13:07:39","slug":"hengruis-hrs9531-and-ar-protac-win-nmpa-ind-approval-for-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53075","title":{"rendered":"Hengrui&#8217;s HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that four drug candidates\u2014<strong>HRS9531<\/strong> (GLP\u20111R\/GIPR dual agonist), <strong>HRS\u20115817<\/strong> (weight\u2011loss drug), <strong>HRS\u20114357<\/strong> (radiotherapeutic), and <strong>HRS\u20115041<\/strong> (AR\u2011PROTAC)\u2014have received <strong>NMPA approval<\/strong> to proceed with clinical trials, positioning Hengrui to compete in the <strong>\u00a5100\u202fbillion+ metabolic and oncology markets<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ind-approvals-summary\">IND Approvals Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Mechanism<\/th><th>Indication<\/th><th>Significance<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>HRS9531<\/strong><\/td><td>GLP\u20111R\/GIPR Dual Agonist<\/td><td>Weight management &amp; diabetes<\/td><td>Challenges Tirzepatide<\/td><td>Phase\u202fI ready<\/td><\/tr><tr><td><strong>HRS\u20115817<\/strong><\/td><td>Class\u202f1 Chemical Drug<\/td><td>Obesity<\/td><td>Significant preclinical weight loss<\/td><td>Phase\u202fI ready<\/td><\/tr><tr><td><strong>HRS\u20114357<\/strong><\/td><td>Radiotherapeutic<\/td><td>PSMA\u2011positive prostate cancer<\/td><td>Combination with HRS\u20115041<\/td><td>Phase\u202fI ready<\/td><\/tr><tr><td><strong>HRS\u20115041<\/strong><\/td><td>AR\u2011PROTAC<\/td><td>Prostate cancer<\/td><td>Overcomes resistance to 2nd\u2011gen AR inhibitors<\/td><td>Phase\u202fI ready<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-hrs9531-glp-1r-gipr-dual-agonist\">HRS9531: GLP\u20111R\/GIPR Dual Agonist<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: Novel dual agonist regulates glucose\/lipid metabolism, suppresses appetite, and enhances insulin sensitivity.<\/p>\n\n\n\n<p><strong>Competitive Landscape<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Standard<\/strong>: Eli Lilly\u2019s <strong>Tirzepatide<\/strong> (Zepbound) \u2013 approved US (Nov\u202f2023) and China (July\u202f2024)<\/li>\n\n\n\n<li><strong>Hengrui\u2019s Edge<\/strong>: HRS9531 enters <strong>Phase\u202fI<\/strong> as the <strong>second domestic dual agonist<\/strong> after <strong>Lilly\u2019s entry<\/strong>, targeting <strong>\u00a580\u202fbillion<\/strong> China GLP\u20111\/GIPR market<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Opportunity<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Weight Management Market<\/strong>: <strong>\u00a550\u202fbillion<\/strong> (2025), projected <strong>\u00a5120\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Diabetes Market<\/strong>: <strong>\u00a545\u202fbillion<\/strong> for injectable GLP\u20111 agents<\/li>\n\n\n\n<li><strong>Pricing<\/strong>: Projected <strong>\u00a5800\u20111,200<\/strong> monthly (vs. Tirzepatide\u2019s <strong>\u00a51,400\u20111,600<\/strong>)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-hrs-5041-ar-protac-for-prostate-cancer\">HRS\u20115041: AR\u2011PROTAC for Prostate Cancer<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: <strong>Androgen Receptor Proteolysis Targeting Chimera<\/strong> designed to <strong>degrade both wild\u2011type and mutant AR proteins<\/strong>, overcoming resistance to second\u2011generation AR inhibitors (enzalutamide, apalutamide).<\/p>\n\n\n\n<p><strong>Clinical Rationale<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prostate Cancer Prevalence<\/strong>: <strong>120,000<\/strong> new cases annually in China; <strong>30\u201140%<\/strong> develop resistance to current therapies<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: China prostate cancer drug market <strong>\u00a518\u202fbillion<\/strong> (2025), growing at <strong>15% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: First AR\u2011PROTAC in <strong>Phase\u202fI<\/strong> in China; potential for <strong>5\u2011year first\u2011mover advantage<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Combination Strategy<\/strong>: Paired with <strong>HRS\u20114357<\/strong> (radiotherapeutic) for <strong>PSMA\u2011positive metastatic disease<\/strong>, creating a <strong>precision oncology doublet<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-hrs-4357-psma-targeted-radiotherapeutic\">HRS\u20114357: PSMA\u2011Targeted Radiotherapeutic<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: <strong>Class\u202f1 innovative radiotherapeutic chemical drug<\/strong> for <strong>PSMA\u2011positive prostate cancer<\/strong>.<\/p>\n\n\n\n<p><strong>Clinical Context<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PSMA Expression<\/strong>: <strong>90%<\/strong> of metastatic prostate cancers express PSMA<\/li>\n\n\n\n<li><strong>Combination Rationale<\/strong>: <strong>Radiotherapy<\/strong> + <strong>AR\u2011PROTAC<\/strong> offers <strong>synergistic tumor killing<\/strong> and <strong>resistance delay<\/strong><\/li>\n\n\n\n<li><strong>Market<\/strong>: PSMA\u2011targeted therapy market projected <strong>\u00a53\u20115\u202fbillion<\/strong> in China by 2030<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications-amp-deal-value\">Financial Implications &amp; Deal Value<\/h2>\n\n\n\n<p><strong>Combined Peak Sales Potential<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HRS9531<\/strong>: \u00a58\u201112\u202fbillion (2030)<\/li>\n\n\n\n<li><strong>HRS\u20115041<\/strong>: \u00a55\u20117\u202fbillion (2031)<\/li>\n\n\n\n<li><strong>HRS\u20114357<\/strong>: \u00a52\u20113\u202fbillion (2031)<\/li>\n\n\n\n<li><strong>HRS\u20115817<\/strong>: \u00a51\u20112\u202fbillion (2029)<\/li>\n\n\n\n<li><strong>Total Portfolio<\/strong>: <strong>\u00a516\u201124\u202fbillion<\/strong> peak sales, representing <strong>15\u201120%<\/strong> of Hengrui\u2019s projected revenue base<\/li>\n<\/ul>\n\n\n\n<p><strong>R&amp;D Investment<\/strong>: <strong>\u00a5400\u2011500\u202fmillion<\/strong> required to advance all four candidates through Phase\u202fIII, leveraging Hengrui\u2019s <strong>6,000+ person R&amp;D team<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Hengrui\u2019s clinical development timelines, market penetration, revenue forecasts, and competitive positioning for HRS9531, HRS\u20115041, HRS\u20114357, and HRS\u20115817. Actual results may differ materially due to clinical trial outcomes, regulatory review timelines, competitive responses, and market access policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026010502850_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026010502850_c.\"><\/object><a id=\"wp-block-file--media-89874b74-953e-48a2-98ac-82d6db3912c0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026010502850_c.pdf\">2026010502850_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026010502850_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-89874b74-953e-48a2-98ac-82d6db3912c0\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026010502850_c-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026010502850_c.\"><\/object><a id=\"wp-block-file--media-4e355f0f-9abb-41e8-9c82-4da87d4f6611\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026010502850_c-1.pdf\">2026010502850_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026010502850_c-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4e355f0f-9abb-41e8-9c82-4da87d4f6611\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that four drug candidates\u2014HRS9531 (GLP\u20111R\/GIPR&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53091,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,2586,4228,86,852,70],"class_list":["post-53075","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-obesity","tag-sha-600276","tag-tpd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui&#039;s HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that four drug candidates\u2014HRS9531 (GLP\u20111R\/GIPR dual agonist), HRS\u20115817 (weight\u2011loss drug), HRS\u20114357 (radiotherapeutic), and HRS\u20115041 (AR\u2011PROTAC)\u2014have received NMPA approval to proceed with clinical trials, positioning Hengrui to compete in the \u00a5100\u202fbillion+ metabolic and oncology markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53075\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui&#039;s HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that four drug candidates\u2014HRS9531 (GLP\u20111R\/GIPR dual agonist), HRS\u20115817 (weight\u2011loss drug), HRS\u20114357 (radiotherapeutic), and HRS\u20115041 (AR\u2011PROTAC)\u2014have received NMPA approval to proceed with clinical trials, positioning Hengrui to compete in the \u00a5100\u202fbillion+ metabolic and oncology markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53075\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T13:07:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-06T13:07:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0601-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53075#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53075\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui&#8217;s HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials\",\"datePublished\":\"2026-01-06T13:07:34+00:00\",\"dateModified\":\"2026-01-06T13:07:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53075\"},\"wordCount\":445,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53075#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0601-1.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"Obesity\",\"SHA: 600276\",\"TPD\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53075#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53075\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53075\",\"name\":\"Hengrui's HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53075#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53075#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0601-1.webp\",\"datePublished\":\"2026-01-06T13:07:34+00:00\",\"dateModified\":\"2026-01-06T13:07:39+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that four drug candidates\u2014HRS9531 (GLP\u20111R\\\/GIPR dual agonist), HRS\u20115817 (weight\u2011loss drug), HRS\u20114357 (radiotherapeutic), and HRS\u20115041 (AR\u2011PROTAC)\u2014have received NMPA approval to proceed with clinical trials, positioning Hengrui to compete in the \u00a5100\u202fbillion+ metabolic and oncology markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53075#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53075\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53075#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0601-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0601-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui's HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53075#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui&#8217;s HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui's HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that four drug candidates\u2014HRS9531 (GLP\u20111R\/GIPR dual agonist), HRS\u20115817 (weight\u2011loss drug), HRS\u20114357 (radiotherapeutic), and HRS\u20115041 (AR\u2011PROTAC)\u2014have received NMPA approval to proceed with clinical trials, positioning Hengrui to compete in the \u00a5100\u202fbillion+ metabolic and oncology markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53075","og_locale":"en_US","og_type":"article","og_title":"Hengrui's HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that four drug candidates\u2014HRS9531 (GLP\u20111R\/GIPR dual agonist), HRS\u20115817 (weight\u2011loss drug), HRS\u20114357 (radiotherapeutic), and HRS\u20115041 (AR\u2011PROTAC)\u2014have received NMPA approval to proceed with clinical trials, positioning Hengrui to compete in the \u00a5100\u202fbillion+ metabolic and oncology markets.","og_url":"https:\/\/flcube.com\/?p=53075","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-06T13:07:34+00:00","article_modified_time":"2026-01-06T13:07:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0601-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53075#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53075"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui&#8217;s HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials","datePublished":"2026-01-06T13:07:34+00:00","dateModified":"2026-01-06T13:07:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53075"},"wordCount":445,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53075#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0601-1.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","Obesity","SHA: 600276","TPD"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53075#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53075","url":"https:\/\/flcube.com\/?p=53075","name":"Hengrui's HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53075#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53075#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0601-1.webp","datePublished":"2026-01-06T13:07:34+00:00","dateModified":"2026-01-06T13:07:39+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that four drug candidates\u2014HRS9531 (GLP\u20111R\/GIPR dual agonist), HRS\u20115817 (weight\u2011loss drug), HRS\u20114357 (radiotherapeutic), and HRS\u20115041 (AR\u2011PROTAC)\u2014have received NMPA approval to proceed with clinical trials, positioning Hengrui to compete in the \u00a5100\u202fbillion+ metabolic and oncology markets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53075#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53075"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53075#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0601-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0601-1.webp","width":1080,"height":608,"caption":"Hengrui's HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53075#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui&#8217;s HRS9531 and AR\u2011PROTAC Win NMPA IND Approval for Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0601-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53075"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53075\/revisions"}],"predecessor-version":[{"id":53092,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53075\/revisions\/53092"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53091"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}